Vanguard Health Care Adm VGHAX

Medalist Rating as of | See Vanguard Investment Hub
  • NAV / 1-Day Return 96.44  /  +0.25 %
  • Total Assets 51.1 Bil
  • Adj. Expense Ratio
    0.300%
  • Expense Ratio 0.300%
  • Distribution Fee Level Low
  • Share Class Type Institutional
  • Category Health
  • Investment Style Large Growth
  • Min. Initial Investment 50,000
  • Status Open
  • TTM Yield 0.76%
  • Turnover 16%

USD | NAV as of Sep 26, 2024 | 1-Day Return as of Sep 26, 2024, 10:17 PM GMT+0

Morningstar’s Analysis VGHAX

Will VGHAX outperform in future?

Get our overall rating based on a fundamental assessment of the pillars below.

Jean Hynes to Step Down as Vanguard Health Care Manager; Ratings Unchanged

null Andrew Redden

Andrew Redden

Analyst Note

Manager Jean Hynes will step down from her portfolio management duties on Vanguard Health Care at the beginning of 2025 to focus on her role as Wellington’s CEO. (Wellington is this strategy’s subadvisor). Hynes, who has delivered strong results since becoming the lead manager in January 2013, has increasingly relied on Wellington’s highly capable team of healthcare investors since assuming the CEO role in 2021. In May 2023, the team promoted Wellington veteran Rebecca Sykes to comanager. Sykes, who joined the firm’s healthcare team in 2007, has worked closely with Hynes for over a decade and is in a good position to succeed her. She possesses deep expertise in healthcare, particularly in pharmaceuticals and biotech, the portfolio’s two largest industries by allocation. Hynes will continue to be available as a valuable resource at Wellington.

Published on

Unlock our full analysis with Morningstar Investor

Portfolio Holdings VGHAX

  • Current Portfolio Date
  • Equity Holdings
  • Bond Holdings
  • Other Holdings
  • % Assets in Top 10 Holdings 43.9
Top 10 Holdings
% Portfolio Weight
Market Value USD
Sector

Eli Lilly and Co

9.63 4.6 Bil
Healthcare

UnitedHealth Group Inc

6.80 3.3 Bil
Healthcare

AstraZeneca PLC

5.63 2.7 Bil
Healthcare

Merck & Co Inc

4.59 2.2 Bil
Healthcare

Novartis AG Registered Shares

3.53 1.7 Bil
Healthcare

Novo Nordisk A/S Class B

3.32 1.6 Bil
Healthcare

Daiichi Sankyo Co Ltd

2.78 1.3 Bil
Healthcare

Danaher Corp

2.62 1.3 Bil
Healthcare

Alnylam Pharmaceuticals Inc

2.55 1.2 Bil
Healthcare

Thermo Fisher Scientific Inc

2.44 1.2 Bil
Healthcare

Sponsor Center